Media Center
Press Releases
12 Jul 17

Back to posts

Pharmaceutical companies are turning to deal making due to falling pipeline productivity, says GBI Research

Although the pharmaceuticals market continues to witness global growth, pharmaceutical and biotechnology companies are facing challenges due to disruptive events in the healthcare market, such as increasing costs of production and R&D, shifts in patent laws, and challenges in the economy, according to business intelligence provider GBI Research.

The company’s latest report states that internally developed pipeline productivity at big pharma companies has decreased recently. Taking discontinued programs into account, the cost of bringing a new drug to market has continued to rise, and is now estimated to exceed $1 billion. In this way, the traditional business model cannot be fruitful in the new market landscape.

Dominic Trewartha, Managing Analyst for GBI Research, explains: “Companies are considering various strategies to overcome current challenges, with deal making the most popular means of boosting revenues over a short period of time. For example, agreements between companies for drug discovery, which allow them to share the risk of co-developing products, have become more common.

“Small companies that primarily carry out early-stage research, development and production activities are now routinely entering into agreements with key industry leaders to out-license the rights to their products, utilizing the strengths of the larger companies in terms of commercializiation expertise, manufacturing, distribution, and marketing capabilities and global presence.”

Key players keen to secure novel and promising molecules are willing to co-operate with small players to in-license promising early-stage assets to expand their portfolios, reduce R&D risks and move ahead in the market.



- Comments provided by Dominic Trewartha, Managing Analyst for GBI Research.

- Information based on GBI Research’s report: Pharmaceutical Deal Trends 2017 Factbook: Partnerships and Acquisitions Shift Focus Towards Early Stage Development, Emerging Markets, and Biologics.

- This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.


GBI Research is a market-leading provider of business intelligence reports,offering actionable data and forecasts based on the insights of key industry leaders to ensure you stayup-to-date with the latest emerging trends in your markets.

For further details, please Contact Us.

Latest Press Releases


Send this to a colleague

I have read and accept terms and conditions and privacy policy